Trial Profile
Phase III study of intravenous immunglobulin (IVIG) in patients with heart failure after myocardial infarction.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Immunoglobulins (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 30 Jul 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Feb 2007 New trial record.